Efficacy and safety of nitazoxanide based quadruple regimen as first line therapy for treating Helicobacter pylori infected naïve patients
The Journal of Infection in Developing Countries · 2025
DOI: 10.3855/jidc.20505 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infection in Developing Countries, 2025. Verfasst von Amro M Hassan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology, Gastroenterology and Infectious Diseases Department, Faculty of Medicine, AL-Azhar University, Assiut, Egypt. Hauptthemen laut MEDLINE: Helicobacter Infections, Thiazoles, Anti-Bacterial Agents, Helicobacter pylori. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Eradication of H. pylori is a challenging issue in many parts of the world including Egypt.
Aim
To evaluate the safety and efficacy of adding nitazoxanide as an adjuvant drug to the standard clarithromycin-based regimen, a single-center phase 4 prospective superiority parallel open-label randomized controlled trial was conducted. Methodology: Two hundred naïve H. pylori-positive patients were randomly distributed into 4 groups in ratio 1:1:1:1; Group 1: 50 patients were treated by clarithromycin 500mg bid, amoxicillin1gm bid, omeprazole 20 mg, Group 2: 50 patients were treated by clarithromycin 500mg bid, metronidazole 500mg bid, omeprazole 20 mg bid, group 3: 50 patients were treated by clarithromycin 500mg bid, nitazoxanide 500mg bid, omeprazole 20 mg bid, and group 4: 50 patients were treated by clarithromycin 500mg bid, amoxicillin1gm bid, nitazoxanide 500mg bid, omeprazole 20 mg bid. All patients were treated for 14 days and assessed 4 weeks after treatment.
Results
Adding nitazoxanide to standard clarithromycin based triple therapy achieved a high eradication rate of 84% in intention to treat analysis (ITT), and 89.36% in per protocol (PP) analysis with high significant p (0.01). Conclusions: adding nitazoxanide as an adjuvant drug to the standard clarithromycin-based regimen is effective and could be used as a first line regimen in the eradication of H. pylori.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hepatology, Gastroenterology and Infectious Diseases Department, Faculty of Medicine, AL-Azhar University, Assiut, Egypt.
- Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Egypt.
- Internal Medicine Department, Faculty of Medicine AL-Azhar University, Assiut, Egypt.
- Clinical Pathology Department, Faculty of Medicine, AL-Azhar University, Assiut, Egypt.
Zitieren
APA
Hassan, A. M., Abdel-Gawad, M., Mahmoud, M. M., Abdelrazzak, E., Sawy, S. S., Sayed, M. A., Ali, R. M. O., El-Nasser, W. S., Hussein, M. A. Y., Izzaldin, M. R., & Mohammed, M. F. (2025). Efficacy and safety of nitazoxanide based quadruple regimen as first line therapy for treating Helicobacter pylori infected naïve patients. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.20505
Vancouver
Hassan AM, Abdel-Gawad M, Mahmoud MM, Abdelrazzak E, Sawy SS, Sayed MA, et al. Efficacy and safety of nitazoxanide based quadruple regimen as first line therapy for treating Helicobacter pylori infected naïve patients. The Journal of Infection in Developing Countries. 2025. doi:10.3855/jidc.20505
BibTeX
@article{Hassan2025,
author = {Hassan, Amro M and Abdel-Gawad, Muhammad and Mahmoud, Maie M and Abdelrazzak, Emad and Sawy, Safwat S and Sayed, Mohamed A and Ali, Rasha Maree O and El-Nasser, Waleed S and Hussein, Mohamed Ahmad Younes and Izzaldin, Mohamed Ramadan and Mohammed, Mohammed F},
title = {Efficacy and safety of nitazoxanide based quadruple regimen as first line therapy for treating Helicobacter pylori infected naïve patients},
journal = {The Journal of Infection in Developing Countries},
year = {2025},
doi = {10.3855/jidc.20505}
}
EUVIMED